FCCC LOGO Faculty Publications
George S , Motzer RJ , Hammers HJ , Redman BG , Kuzel TM , Tykodi SS , Plimack ER , Jiang J , Waxman IM , Rini BI
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial
JAMA Oncol. 2016 Sep 01;2(9) :1179-86
PMID: 27243803    PMCID: PMC5568541    URL: http://www.ncbi.nlm.nih.gov/pubmed/27243803
Back to previous list
Abstract
Importance: Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. Objective: To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC). Design, Setting, and Participants: Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression. Interventions: Nivolumab 0.3, 2, or 10 mg/kg intravenously every 3 weeks. Main Outcomes and Measures: Safety and efficacy of nivolumab treatment. Results: Of 168 patients (median [range] age, 61 [37-81] years; 72% male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for </=6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14% (5 patients) and 16% (15 patients), and median progression-free survival was 4.2 (95% CI, 2.8-5.5) and 2.6 (95% CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69%) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81%]) vs those not treated beyond progression (n = 61 [66%]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression). Conclusions and Relevance: In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression. Trial Registration: clinicaltrials.gov Identifier: NCT01354431.
Notes
George, Saby Motzer, Robert J Hammers, Hans J Redman, Bruce G Kuzel, Timothy M Tykodi, Scott S Plimack, Elizabeth R Jiang, Joel Waxman, Ian M Rini, Brian I JAMA Oncol. 2016 May 12. doi: 10.1001/jamaoncol.2016.0775.